Literature DB >> 12707398

Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane.

Siska Mortier1, An S De Vriese, Rachel M McLoughlin, Nicholas Topley, Thomas P Schaub, Jutta Passlick-Deetjen, Norbert H Lameire.   

Abstract

Peritonitis remains an important cause of morbidity and technique failure in peritoneal dialysis (PD). Conventional peritoneal dialysate fluids (PDF) inhibit peritoneal leukocyte function in vitro and may thus adversely affect the immune response to peritonitis. New PDF have been designed with neutral pH, low glucose degradation product (GDP) contents, and bicarbonate as buffer. The present intravital microscopy study examined the effects of conventional and new PDF on leukocyte behavior in the peritoneal microcirculation of Wistar rats. The visceral peritoneum was superfused by a control solution (EBSS), a conventional (CAPD), or a new bicarbonate-buffered PDF with neutral pH and low GDP content (CAPD BicaVera). In addition, spent conventional and new PDF were tested. The number of rolling, adhering, and extravasated leukocytes and leukocyte rolling velocity were assessed at different time intervals after exposure to lipopolysaccharide (LPS) or cell-free supernatants of coagulase-negative staphylococci (CNS-CFS). Exposure to LPS or CNS-CFS dissolved in EBSS dramatically increased the number of rolling, adhering and extravasated leukocytes and decreased leukocyte rolling velocity. Superfusion by CAPD abolished the LPS- or CNS-CFS-induced leukocyte recruitment, whereas CAPD BicaVera had significantly fewer depressant effect. Spent PDF affected the leukocyte response in a similar way as fresh PDF. High lactate concentrations, GDP, and hypertonicity appeared to be mainly responsible for the inhibition of leukocyte recruitment. In conclusion, conventional PDF abolish in vivo leukocyte recruitment in response to potent inflammatory stimuli. Bicarbonate-buffered pH-neutral PDF with low GDP contents have fewer depressant effects and may therefore contribute to a better preservation of peritoneal host defense.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707398     DOI: 10.1097/01.asn.0000060681.91079.30

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  19 in total

Review 1.  New peritoneal dialysis fluids: practical use for children.

Authors:  Cornelis H Schröder
Journal:  Pediatr Nephrol       Date:  2003-11       Impact factor: 3.714

2.  Peritonitis in the patient on peritoneal dialysis: does the composition of the dialysis fluid make a difference?

Authors:  Danica Lam; Joanne M Bargman
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 8.237

3.  Peritoneal Dialysis Catheter Increases Leukocyte Recruitment in the Mouse Parietal Peritoneum Microcirculation and Causes Fibrosis.

Authors:  Paulina M Kowalewska; Peter J Margetts; Alison E Fox-Robichaud
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

4.  Influence of bicarbonate/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells.

Authors:  Antonio Fernández-Perpén; María Luisa Pérez-Lozano; María-Auxiliadora Bajo; Patricia Albar-Vizcaino; Pilar Sandoval Correa; Gloria del Peso; María-José Castro; Abelardo Aguilera; Marta Ossorio; Mirjam E Peter; Jutta Passlick-Deetjen; Luiz S Aroeira; Rafael Selgas; Manuel López-Cabrera; J Antonio Sánchez-Tomero
Journal:  Perit Dial Int       Date:  2012-01-03       Impact factor: 1.756

Review 5.  An update on peritoneal dialysis solutions.

Authors:  Elvia García-López; Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

6.  The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

7.  Complement Activation in Peritoneal Dialysis-Induced Arteriolopathy.

Authors:  Maria Bartosova; Betti Schaefer; Justo Lorenzo Bermejo; Silvia Tarantino; Felix Lasitschka; Stephan Macher-Goeppinger; Peter Sinn; Bradley A Warady; Ariane Zaloszyc; Katja Parapatics; Peter Májek; Keiryn L Bennett; Jun Oh; Christoph Aufricht; Franz Schaefer; Klaus Kratochwill; Claus Peter Schmitt
Journal:  J Am Soc Nephrol       Date:  2017-10-18       Impact factor: 10.121

8.  Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kym M Bannister; Philip A Clayton; David W Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 8.237

Review 9.  Protective measures against ultrafiltration failure in peritoneal dialysis patients.

Authors:  Anna Rita Aguirre; Hugo Abensur
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  Biocompatible peritoneal dialysis fluids: clinical outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Kathryn Wiggins; David W Johnson
Journal:  Int J Nephrol       Date:  2012-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.